Breast Care最新文献

{"title":"Quality of Life in Patients Pre- and Post-Breast Reduction Surgery in a South African Population: A Single-Centred Patient-Based Study.","authors":"Nokubonga Khwela, Anil Madaree, Nivana Mohan, Lelika Lazarus","doi":"10.1159/000543306","DOIUrl":"https://doi.org/10.1159/000543306","url":null,"abstract":"<p><strong>Introduction: </strong>Breast hypertrophy is the abnormal enlargement of breast tissue resulting in extremely large breasts and is a regular condition among women worldwide. It can affect different aspects of their life, including their psycho-social, sexual, emotional, and physical well-being. This study aimed to assess the quality of life in individuals with breast hypertrophy both before and after undergoing breast reduction surgery.</p><p><strong>Methods: </strong>Two sets of questionnaires (preoperative and post-operative) were formulated and distributed to 18 patients (median age of 31, age range: 18-48 years) undergoing breast reduction surgery. Patients were also provided with an informed consent form.</p><p><strong>Results: </strong>Preoperatively, most patients expressed different levels of dissatisfaction with themselves across all categories. However, post-operatively, significant levels (<i>p</i> < 0.05, <i>p</i> < 0.001) of satisfaction were demonstrated by patients, as 100% of them reported a reduction in back pain and heaviness of breasts, and 100% reported improvement in their self-confidence. Also, 94% and 65% reported improvement in their social interaction and sexual life, respectively, while 83% and 61% of patients reported satisfaction in carrying their grocery shopping bags and their engagement in regular exercise programs, respectively.</p><p><strong>Conclusion: </strong>The study illustrates that breast reduction surgery had a positive effect on the quality of life of patients as a significant proportion of them reported improvement and satisfaction across all categories following the procedure.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-11"},"PeriodicalIF":2.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Banana Supplementation for Breast Cancer Surgery Patients: A Two-Center Experience.","authors":"Yang Jiang, Xin Ma, Lei Niu, Yaoyao Jiang","doi":"10.1159/000545174","DOIUrl":"https://doi.org/10.1159/000545174","url":null,"abstract":"<p><strong>Introduction: </strong>Patients frequently encounter both physical and mental challenges after undergoing surgery for breast cancer, leading to a negative impact on their general well-being. Our objective was to investigate the beneficial effects of dietary supplementation with bananas on patients after breast cancer surgery.</p><p><strong>Methods: </strong>Among breast cancer patients who had undergone breast surgery, the banana group (<i>n</i> = 77) consumed an additional banana daily alongside their regular diet, while the non-banana group (<i>n</i> = 77) did not. Negative emotions, sleep quality, sexual health, complication rates, length of hospital stay, and quality of life were assessed.</p><p><strong>Results: </strong>Compared to the non-banana group, patients in the banana group exhibited lower levels of depression and anxiety, better sleep quality, more satisfactory sexual quality of life, and a higher overall quality of life postoperatively. Nonetheless, the complication rates and length of hospital stay did not show any notable variances between the 2 groups.</p><p><strong>Conclusion: </strong>This study highlights the novel finding that simple dietary supplementation with bananas significantly enhances mental well-being and overall quality of life in breast cancer patients following surgery, despite no notable impact on physical recovery metrics.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-10"},"PeriodicalIF":2.0,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do We Need Anthracyclines for Elderly Patients with Triple-Negative Breast Cancer?","authors":"Stefan Lukac, Visnja Fink, Thomas W P Friedl, Franziska Mergel, Kerstin Pfister, Henning Schäffler, Davut Dayan, Sabine Heublein, Brigitte Rack, Wolfgang Janni, Elena Leinert","doi":"10.1159/000544906","DOIUrl":"https://doi.org/10.1159/000544906","url":null,"abstract":"<p><strong>Objectives: </strong>Triple-negative breast cancer (TNBC) requires chemotherapy-based systemic treatment which is usually anthracycline-based (AB). The cardiotoxicity of AB regimens is especially relevant in the elderly population. Therefore, we retrospectively compared survival and toxicity between elderly patients with early TNBC receiving AB or anthracycline-free (AF) adjuvant chemotherapy to evaluate whether elderly patients with TNBC could be spared anthracycline-related toxicity without compromising survival.</p><p><strong>Methods: </strong>The study population comprised 221 women with TNBC older than 65 years from the SUCCESS A and SUCCESS C studies, who underwent primary surgery and received either AB (3x fluorouracil-epirubicin-cyclophosphamide followed by 3x docetaxel) or AF (6x docetaxel-cyclophosphamide) adjuvant chemotherapy according to a standardized protocol. The two groups were compared regarding clinicopathological parameters (pT, pN, grading, histological subtype, type of surgery, adjuvant radiotherapy) and side effects using chi-square tests, and regarding survival (overall survival, invasive disease-free survival, breast-cancer specific survival, distant disease-free survival) using log-rank tests and Cox regressions.</p><p><strong>Results: </strong>There was no significant difference between the two groups regarding any of the clinicopathological parameters, and no significant difference was observed in survival parameters. However, elderly patients with the AB regime had significantly more often grade 3 or 4 adverse events (75.2% vs. 50.6%, <i>p</i> < 0.001) during adjuvant chemotherapy than patients with the AF regimen.</p><p><strong>Conclusion: </strong>In our retrospective analysis of SUCCESS A and C trial, the use of AF chemotherapy in elderly patients with TNBC was associated with similar survival rates but less toxicity compared to AB chemotherapy. Further randomized controlled trials with AF regimen focusing on elderly patients with TNBC are necessary to confirm our results.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-9"},"PeriodicalIF":2.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025.","authors":"Tjoung-Won Park-Simon, Volkmar Müller, Ute-Susann Albert, Maggie Banys-Paluchowski, Rupert Bartsch, Ingo Bauerfeind, Vesna Bjelic-Radisic, Jens-Uwe Blohmer, Wilfried Budach, Peter Dall, Nina Ditsch, Eva M Fallenberg, Peter A Fasching, Tanja Fehm, Michael Friedrich, Bernd Gerber, Oleg Gluz, Nadia Harbeck, Andreas Daniel Hartkopf, Jörg Heil, Juliane Hörner-Rieber, Jens Huober, Hans-Heinrich Kreipe, David Krug, Thorsten Kühn, Sherko Kümmel, Sibylle Loibl, Diana Lüftner, Michael Patrick Lux, Nicolai Maass, Christoph Mundhenke, Toralf Reimer, Mattea Reinisch, Kerstin Rhiem, Achim Rody, Marcus Schmidt, Andreas Schneeweiss, Florian Schütz, Hans-Peter Sinn, Christine Solbach, Erich-Franz Solomayer, Elmar Stickeler, Christoph Thomssen, Michael Untch, Marion Tina van Mackelenbergh, Isabell Witzel, Achim Wöckel, Rachel Wuerstlein, Wolfgang Janni, Marc Thill","doi":"10.1159/000545019","DOIUrl":"https://doi.org/10.1159/000545019","url":null,"abstract":"<p><p>The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2025 update of the evidence-based recommendations for the diagnosis and treatment of patients with early breast cancer.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-19"},"PeriodicalIF":2.0,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11996201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025.","authors":"Marc Thill, Wolfgang Janni, Ute-Susann Albert, Maggie Banys-Paluchowski, Rupert Bartsch, Ingo Bauerfeind, Vesna Bjelic-Radisic, Jens Blohmer, Wilfried Budach, Peter Dall, Nina Ditsch, Eva Maria Fallenberg, Peter A Fasching, Tanja Fehm, Michael Friedrich, Bernd Gerber, Oleg Gluz, Nadia Harbeck, Andreas Hartkopf, Jörg Heil, Juliane Hörner-Rieber, Jens Huober, Hans-Heinrich Kreipe, David Krug, Thorsten Kühn, Sherko Kümmel, Sibylle Loibl, Diana Lüftner, Michael Patrick Lux, Nicolai Maass, Christoph Mundhenke, Mattea Reinisch, Toralf Reimer, Kerstin Rhiem, Achim Rody, Marcus Schmidt, Andreas Schneeweiss, Florian Schütz, Hans-Peter Sinn, Christine Solbach, Erich-Franz Solomayer, Elmar Stickeler, Christoph Thomssen, Michael Untch, Marion van Mackelenbergh, Isabell Witzel, Achim Wöckel, Rachel Würstlein, Volkmar Müller, Tjoung-Won Park-Simon","doi":"10.1159/000545018","DOIUrl":"https://doi.org/10.1159/000545018","url":null,"abstract":"<p><p>The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO; German Gynecological Oncology Group) presents the 2025 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer (mBC).</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-12"},"PeriodicalIF":2.0,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Interreader Agreement between Optimized Short and Full Breast MRI Protocols for Screening Breast Cancer in Moderate- and High-Risk Women.","authors":"Agnaldo Lopes da Silva Filho, Mariana Mitraud Ottoni Guedes, Thais Paiva Moraes, Adriene Moraes Campos, Ivie Braga de Paula, Felipe Marcondes de Oliveira Coelho, Barbara Silveira Santana, Bertha Andrade Coelho, Letícia Martins de Araújo Campos Linhares, Henrique Lima Couto","doi":"10.1159/000543958","DOIUrl":"https://doi.org/10.1159/000543958","url":null,"abstract":"<p><strong>Introduction: </strong>The optimized short breast MRI protocol for breast cancer screening was developed to address some limitations of the complete protocol, such as long examination duration and high cost. This study aimed to evaluate the intraobserver agreement between optimized short and complete protocols in the interpretation of breast MRI images. Specifically, we assessed the acquisition and reading times of the images, as well as the time required for report generation.</p><p><strong>Methods: </strong>A cross-sectional study was conducted in asymptomatic women with high breast density, at moderate and high risk, who underwent breast MRI in private institutions in Belo Horizonte, MG, Brazil. An optimized short protocol was simulated on a computer by selecting images from the complete examination. The examinations were read independently, with BI-RADS categories assigned. Intraobserver agreement between this shorter protocol and the complete protocol was assessed.</p><p><strong>Results: </strong>A total of 170 women were included. A 100% BI-RADS agreement rate was observed in categories 1 and 2, an 80.95% agreement rate in category 3, and a 93.75% agreement rate in category 4 between the protocols. The unweighted kappa value was 0.955 (95% confidence interval [CI] 0.916-0.993), while the weighted kappa value was 0.969 (95% CI: 0.943-0.995). Furthermore, the optimized short protocol reduced examination duration by 21 min.</p><p><strong>Conclusion: </strong>The optimized short breast MRI protocol provides a time-efficient alternative for breast cancer screening in moderate- to high-risk populations with dense breasts while maintaining strong agreement in BI-RADS classification. This protocol reduces costs and enhances patient tolerability, thereby improving accessibility to breast MRI.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-7"},"PeriodicalIF":2.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11981293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Preferences for HR+/HER2- Early Breast Cancer Adjuvant Treatment: A Multicountry Discrete Choice Experiment.","authors":"Victoria Harmer, Cathy Ammendolea, Mandy Ryan, Frances Boyle, Gustavo Werutsky, Dina El Mouzain, Deborah A Marshall, Caitlin Thomas, Sebastian Heidenreich, Hui Lu, Nicolas Krucien, Juan Mora Payan, Dawn Aubel, Andriy Danyliv, Purnima Pathak, Nadia Harbeck","doi":"10.1159/000543320","DOIUrl":"10.1159/000543320","url":null,"abstract":"<p><strong>Introduction: </strong>More adjuvant treatment options are becoming available for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) based on results of clinical trials. This study quantified the importance of different attributes of EBC adjuvant therapies to patients and the benefit-risk tradeoffs patients were willing to make.</p><p><strong>Methods: </strong>Women with HR+/HER2- EBC completed an online discrete choice experiment (DCE) survey; the design was informed by clinical data, qualitative interviews (<i>n</i> = 40), and pre-testing interviews (<i>n</i> = 40). Participants (pts) made 10 choices between pairs of hypothetical treatments described by varying levels of 6 attributes. DCE data were analyzed using a correlated mixed logit model. Relative attribute importance scores captured the impact of each attribute across clinically relevant ranges. Benefit-risk tradeoffs were captured as the minimum improvements in 5-year invasive disease-free survival (iDFS) that pts would require to tolerate increases in therapy-associated adverse event (AE) risks.</p><p><strong>Results: </strong>A total of 866 patients from the USA, France, Spain, Canada, the UK, Germany, South Korea, and Australia completed the DCE (mean age: 57.7 years; 76% postmenopausal; 29% stage I disease, 55% stage II, 16% stage III). Improved 5-year iDFS (75.4-82.7% range; associated with combination regimens [CRs] vs. endocrine therapy [ET] alone) contributed the most to treatment preferences (clinically relevant relative attribute importance: 38.4%), followed by reduced risks of venous thromboembolic events (VTEs) (20.4%), neutropenia (20.3%), and diarrhea (15.0%). Treatment type + duration (3.7%) and fatigue (2.3%) were less important. Pts required the largest improvement in 5-year iDFS (3.9%) to tolerate increased risks of VTE (0.7%-2.5%) or neutropenia (5.6%-46%); willingness to accept tradeoffs depended on the AE. Preference heterogeneity was observed across subgroups, but 5-year iDFS improvement was consistently the most impactful on treatment choice in all subgroups.</p><p><strong>Conclusion: </strong>A multicountry sample of patients most valued adjuvant therapies with higher 5-year iDFS and may therefore prefer CRs over ET alone. The value of CRs depends on their specific safety profiles, and shared decision-making should consider this to select treatment options that align with individual preferences.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 1","pages":"16-26"},"PeriodicalIF":2.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Importance of Panimmune-Inflammation Value and PILE Scores in Non-Metastatic Luminal A Breast Cancer.","authors":"Mukaddes Yılmaz, Eda Erdiş, Mahmut Uçar, Birsen Yücel","doi":"10.1159/000543304","DOIUrl":"10.1159/000543304","url":null,"abstract":"<p><strong>Introduction: </strong>The present study evaluated the prognostic significance of panimmune-inflammation value (PIV) and PILE (a composite score of PIV, lactate dehydrogenase [LDH], and Eastern Cooperative Oncology Group Performance Status [ECOG PS]) in patients with non-metastatic luminal A breast cancer.</p><p><strong>Methods: </strong>Non-metastatic stage (I-III) luminal A breast cancer patients who were admitted to Cumhuriyet University Oncology Center were retrospectively examined. The PIV score was calculated using the neutrophil, platelet, monocyte, and lymphocyte counts at the time of diagnosis. The PIV, LDH, and ECOG PS parameters were used for the PILE score.</p><p><strong>Results: </strong>A total of 293 patients were included. The median PIV was 254.89; 239 (82%) patients had low PILE score; and 54 (18%) patients had high PILE score. Patients with low PIV and low PILE scores had significantly better OS and disease-free survival (DFS) (PIV; <i>p</i> = 0.033 for OS and <i>p</i> = 0.024 for DFS and PILE; <i>p</i> = 0.001 for OS and <i>p</i> = 0.005 for DFS). The PIV and PILE scores were found to be significant prognostic factors associated with OS and DFS. The PIV score was found to be an independent prognostic factor for OS and DFS (OS: score 0 vs. 1; HR: 1.89, 95% CI: 1.06-3.35; <i>p</i> = 0.029; and DFS: score 0 vs. 1; HR: 1.75, 95% CI: 1.01-3.01; <i>p</i> = 0.044). The PILE score was not an independent prognostic factor associated with OS or DFS.</p><p><strong>Conclusion: </strong>Survival was better in those with lower PIV and PILE scores. The PIV score was an independent prognostic factor for survival in these patients.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 1","pages":"27-39"},"PeriodicalIF":2.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert Discussion: ESMO 2024.","authors":"Christoph Thomssen, Maggie Banys-Paluchowski, François-Clément Bidard, Nancy U Lin","doi":"10.1159/000543115","DOIUrl":"https://doi.org/10.1159/000543115","url":null,"abstract":"","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 1","pages":"40-44"},"PeriodicalIF":2.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors for Upgrade to Breast Cancer in Patients with B3 Lesions Diagnosed by Core Biopsy: A Retrospective Cohort Study.","authors":"Burak Dinçer, Ceylan Yanar, Ramazan Uçak, Esma Çerekçi, Cemal Kaya","doi":"10.1159/000542551","DOIUrl":"10.1159/000542551","url":null,"abstract":"<p><strong>Background: </strong>The optimal approach to B3 lesions is controversial, and the risk of malignant upgrade varies between studies. This study aimed to evaluate the factors affecting the risk of upgrading to breast cancer in patients diagnosed with B3 lesions by core biopsy.</p><p><strong>Methods: </strong>A total of 410 patients diagnosed with B3 lesions by core biopsy and subsequently undergoing surgical excision were evaluated. Patients who did not undergo surgical excision or were not followed up at our center were excluded. Patients were analyzed based on demographic, clinical, radiological, and pathological findings.</p><p><strong>Results: </strong>All 410 patients included in the study were women, with a median age of 47 years (range 21-78). An upgrade to in situ or invasive disease was observed in 117 of the 410 patients (28.5%). In univariate analysis, age, mammographic findings, histopathological type, and atypia in core biopsy were identified as significant factors affecting the upgrade rate (<i>p</i> = 0.046, <i>p</i> = 0.028, <i>p</i> < 0.001, and <i>p</i> < 0.001, respectively). In multivariate analysis, the presence of atypia (<i>p</i> < 0.001) and a diagnosis of atypical ductal hyperplasia (ADH) (<i>p</i> = 0.026) were determined to be independent variables that increase the upgrade rate.</p><p><strong>Conclusion: </strong>Surgical excision or vacuum-assisted excision may be more appropriate for ADH and B3 lesions with atypia on core biopsy.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 1","pages":"1-7"},"PeriodicalIF":2.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}